Table of Contents Table of Contents
Previous Page  78 / 80 Next Page
Information
Show Menu
Previous Page 78 / 80 Next Page
Page Background

76

NCCN Guidelines for Patients

®

:

Kidney Cancer, Version 1.2017

Index

Index

active surveillance

32–33, 43–45

adrenal gland

8–9, 13, 24, 26–27, 31, 41, 44, 49

angiogenesis

34, 53

biopsy

21–22, 45, 47–48, 59

blood test

19–20, 45–50, 54–55

cancer stage

6, 24, 27–28, 50

carcinoma

6, 12, 14

clear cell RCC

22, 52–53, 56

computed tomography (CT)

16–18, 21, 24–25, 33,

45, 47–50, 54–55

cytokine therapy

37, 41, 53, 56

cytoreductive nephrectomy

32, 51

first-line treatment

52, 54, 56

follow-up test

44–51, 54–55

Gerota’s fascia

9, 13, 26–27, 51

imaging test

16–19, 24–25, 31, 33, 45–50, 54–55

immunotherapy

34, 37, 41, 53, 56

kidney function

18, 30, 32, 44, 46, 50, 54

magnetic resonance imaging (MRI)

18, 24, 33,

45–50, 55

metastasectomy

32, 51, 54

non-clear cell RCC

22, 52–53

partial nephrectomy

30, 41, 43–44, 47, 49–50

primary treatment

30, 29, 41, 43–44, 49–51

radical nephrectomy

31–32, 41, 43–44, 46–49

renal vein

10, 26, 31

side effect

16, 28, 30, 32–41, 44, 46, 52–54, 56

staging

24–28, 45–46, 50, 54

supportive care

39–41, 54, 56

surgery

21–22, 30–33, 39–41, 43–44, 46–52, 54, 56,

60

targeted therapy

34–37, 41, 53

thermal ablation

33, 43–44, 47–48

tyrosine kinase inhibitor (TKI)

34–35, 53

vena cava

10, 24, 26, 31